Table 2: CMS alters TLRs signaling pathway gene expression profile in aortas of apoE-/- mice. ApoE-/- mice 4 weeks old were subjected to a 24-hour CMS daily for 0, 4, 12 weeks. Mice were sacrificed, and aortas were harvested. Total RNA was extracted, and microarray analysis was determined as described under “materials and methods.” TLRs signaling pathway array consisting of 87 were used to analyze gene expression in aorta from mice with or without chronic mild stress. The microarrays were used according to the manufacturer's instructions. The table showed gene expression changes 2.0-fold versus control. Calculate the fold change for each gene from control group to stress group as 2-ΔΔCt. Among 87 genes analyzed, 15 genes were upregulated, and 28 genes were downregulated by CMS.
(a) Genes upregulated in aorta of mice exposure to CMS compared with control mice (n  = 5)

WellSymbolDescriptionFold increase -value

A03Ccl2Chemokine (C-C motif) ligand 25.3.02
A04Cd14CD14 antigen2.4.013
A09Clec4eC-type lectin domain family 4, member e3.88.026
A10Csf2Colony stimulating factor 2 (granulocyte-macrophage)2.06.018
C03Il1bInterleukin 1 beta11.67.008
C06Il6Interleukin 63.54.018
C08Irak1Interleukin-1 receptor-associated kinase 12.78.016
D12Myd88Myeloid differentiation primary response gene 883.62.032
E04NfkbibNuclear factor of kappa light chain gene enhancer in B-cells inhibitor, beta2.61.041
E05Nfkbil1Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-like 13.35.035
E09Pglyrp1Peptidoglycan recognition protein 15.84.011
F02RelaV-rel reticuloendotheliosis viral oncogene homolog A (avian)2.17.031
F11Tlr4Toll-like receptor 44.04.014
G05TnfTumor necrosis factor2.15.018
H03Hsp90ab1Heat shock protein 90kDa alpha (cytosolic), class B member 12.05.012

(b) Genes downregulated in aorta of mice exposure to CMS compared with control mice (n  = 5)

WellSymbolDescriptionFold decrease -value

A01BtkBruton agammaglobulinemia tyrosine kinase−3.13.011
A02Casp8Caspase 8−2.26.024
A11Csf3Colony stimulating factor 3 (granulocyte)−8.03.032
B01Elk1ELK1, member of ETS oncogene family−2.47.021
B03FosFBJ osteosarcoma oncogene−2.06.013
C01Il12aInterleukin 12A−2.67.028
C07Il6raInterleukin 6 receptor, alpha−2.9.022
C09Irak2Interleukin-1 receptor-associated kinase 2−2.08.037
C11Irf3Interferon regulatory factor 3−4.33.019
C12JunJun oncogene−2.06.042
D01LtaLymphotoxin A−13.13.011
D02Muc13Mucin 13, epithelial transmembrane−2.12.016
D10Mapk8ip3Mitogen-activated protein kinase 8 interacting protein 3−6.89.027
E02Nfkb2Nuclear factor of kappa light polypeptide gene enhancer in B-cells−2.06.036
E06NfrkbNuclear factor related to kappa B binding protein−4.94.012
E07Nr2C2Nuclear receptor subfamily 2, group C, member 2−3.24.028
E08Peli1Pellino 1−2.45.023
F01Mapk8Mitogen-activated protein kinase 8−2.34.026
F05Ticam1Toll-like receptor adaptor molecule 1−24.17.003
F06Ticam2Toll-like receptor adaptor molecule 2−2.4.044
F08Tlr1Toll-like receptor 2−2.05.032
F12Tlr5Toll-like receptor 5−6.57.026
G04Tlr9Toll-like receptor 9−5.37.022
G06Tnfaip3Tumor necrosis factor, alpha-induced protein 3−4.81.023
G10Traf6Tnf receptor-associated factor 6−2.52.034
G11Ube2nUbiquitin-conjugating enzyme E2N−2.39.028
H04GapdhGlyceraldehyde-3-phosphate dehydrogenase−3.26.032
H05ActbActin, beta, cytoplasmic−2.63.025